Your browser doesn't support javascript.
loading
Radiochemotherapy with or without cetuximab for unresectable esophageal cancer: final results of a randomized phase 2 trial (LEOPARD-2).
Rades, Dirk; Bartscht, Tobias; Hunold, Peter; Schmidberger, Heinz; König, Laila; Debus, Jürgen; Belka, Claus; Homann, Nils; Spillner, Patrick; Petersen, Cordula; Kuhnt, Thomas; Fietkau, Rainer; Ridwelski, Karsten; Karcher-Kilian, Kerstin; Kranich, Anne; Männikkö, Sofia; Schild, Steven E; Maderer, Annett; Moehler, Markus.
  • Rades D; Department of Radiation Oncology, University of Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Germany. Rades.Dirk@gmx.net.
  • Bartscht T; Department of Hematology and Oncology, University of Lübeck, Lübeck, Germany.
  • Hunold P; Department of Radiology and Nuclear Medicine, University of Lübeck, Lübeck, Germany.
  • Schmidberger H; Department of Radiation Oncology, Johannes-Gutenberg University Mainz, Mainz, Germany.
  • König L; Department of Radiation Oncology, University of Heidelberg, Heidelberg, Germany.
  • Debus J; Department of Radiation Oncology, University of Heidelberg, Heidelberg, Germany.
  • Belka C; Department of Radiation Oncology, Ludwig-Maximillians University, Munich, Germany.
  • Homann N; Medical Department II, Klinikum Wolfsburg, Wolfsburg, Germany.
  • Spillner P; Department of Radiation Oncology, Eberhard-Karls University, Tübingen, Germany.
  • Petersen C; Department of Radiotherapy and Radiation Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Kuhnt T; Department of Radiation Oncology, University Hospital Leipzig, Leipzig, Germany.
  • Fietkau R; Department of Radiation Oncology, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.
  • Ridwelski K; Department of General and Visceral Surgery, Klinikum Magdeburg, Magdeburg, Germany.
  • Karcher-Kilian K; Practice for Gastroenterology, Diabetology, Oncology and Hematology Lübeck, Lübeck, Germany.
  • Kranich A; Gesellschaft für Studienmanagement und Onkologie mbH, Hamburg, Germany.
  • Männikkö S; Pharma Ltd, Turku, Finland.
  • Schild SE; Department of Radiation Oncology, Mayo Clinic Scottsdale, AZ, USA.
  • Maderer A; 1st Department of Internal Medicine, Johannes Gutenberg-University Mainz, Mainz, Germany.
  • Moehler M; 1st Department of Internal Medicine, Johannes Gutenberg-University Mainz, Mainz, Germany.
Strahlenther Onkol ; 196(9): 795-804, 2020 Sep.
Article en En | MEDLINE | ID: mdl-32533228
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Esofágicas / Quimioradioterapia / Cetuximab / Antineoplásicos Inmunológicos Tipo de estudio: Clinical_trials Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Esofágicas / Quimioradioterapia / Cetuximab / Antineoplásicos Inmunológicos Tipo de estudio: Clinical_trials Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Año: 2020 Tipo del documento: Article